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Chronic Mitral Regurgitation and Aortic Regurgitation
Have Indications for Surgery Changed?
Robert O. Bonow, MD, MS
Chicago, Illinois
The timing of surgery in patients with mitral regurgitation (MR) and aortic regurgitation (AR) continues to elicit
uncertainty and considerable controversy. Some patients will incur myocardial structural changes, pulmonary
hypertension, or arrhythmias before they manifest symptoms, with the risk that these adverse endpoints will not
be reversible after valve repair or replacement. Imaging to assess valve morphology, severity of regurgitation,
and left ventricular (LV) volume and function is firmly established, and the guidelines of the American College of
Cardiology/American Heart Association and the European Society of Cardiology support this approach. However,
with improvement in surgical technique and outcomes, there is momentum toward earlier intervention before
patients reach class I indications of symptoms or LV systolic dysfunction, particularly in patients with degenera-
tive MR who are candidates for mitral repair. In expert centers, mitral valve repair is achieved at low risk and
with excellent long-term durability of repair, returning patients to a lifespan equivalent to that of the normal pop-
ulation. In AR, decision making is more complex because patients almost invariably require valve replacement.
Prospective clinical trials are needed to provide the evidence base for more objective decisions regarding timing
of surgery. Biomarkers and new methods to assess interstitial fibrosis and regional myocardial function have
also evolved for clinical investigation and hold the promise of enhanced determination of those in whom early
surgical intervention is warranted. (J Am Coll Cardiol 2013;61:693–701) © 2013 by the American College of
Cardiology Foundation






hMajor advances in the evaluation and management of
patients with valvular heart disease during the past half
century have improved the survival and quality of life for
patients with mitral and aortic valve disease. Enhanced
diagnosis, understanding of natural history, and striking
improvements in surgical valve repair and replacement have
completely transformed the approach to patients with mitral
regurgitation (MR) and aortic regurgitation (AR). The
surgical windows have expanded to encompass both older
patients with severe comorbidities and younger patients
earlier in the natural history of their disease, to include even
those who are asymptomatic. Rather than waiting to operate
until patients are severely symptomatic and have impaired
left ventricular (LV) function, which was the paradigm 50
years ago, current clinical strategies now emphasize earlier
intervention in many patients before the onset of symptoms,
LV dysfunction, and other adverse endpoints such as
pulmonary hypertension and atrial fibrillation. These latter
trends are especially pertinent in patients who have MR and
AR because the chronic LV volume overload may lead to
irreversible LV dysfunction before the onset of symptoms.
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2012, accepted August 21, 2012.The American College of Cardiology/American Heart
Association (ACC/AHA) and the European Society of
Cardiology/European Association for Cardio-Thoracic
Surgery (ESC/EACTS) practice guidelines for manage-
ment of patients with valvular heart disease represent a
major step toward improving and standardizing patients’
quality of care (1,2). The ESC/EACTS guidelines were
revised in 2012, and the ACC/AHA guidelines are cur-
rently undergoing revision. However, there are unique
hurdles in developing and implementing guidelines in this
field. There is a paucity of prospective clinical trials address-
ing management of valve disease, and the published litera-
ture primarily represents the retrospective experiences of
single institutions in relatively small numbers of patients.
Virtually all of the recommendations in both guidelines are
based on expert consensus (Level of Evidence: C). In the
ACC/AHA valve guidelines, only 1 of 320 recommenda-
tions (0.3%) was based on Level of Evidence: A data (3). It
s thus remarkable that the ACC/AHA and ESC/EACTS
uidelines are concordant in the majority of their
ecommendations.
Changes in clinical practice, with new imaging methods,
reater surgical experience, and a trend toward earlier
urgery in patients with regurgitant lesions, raise the ques-
ion of whether the indications for surgical intervention
ave evolved beyond the current guidelines for some pa-
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referring cardiologist and the ex-
pertise of the surgical team. A





Class I recommendations for
surgery in the ACC/AHA and
ESC/EACTS guidelines (1,2) for
patients with degenerative MR
(predominantly mitral valve pro-
lapse [MVP] from myxomatous
disease and fibroelastic deficiency)
include patients with symptoms
and those with asymptomatic LV
systolic dysfunction (Table 1). Be-
cause LV shortening may be en-
hanced in the setting of severeMR
by the ability to unload into the
low-impedance left atrium, LV
dysfunction in severe MR is de-
fined as an ejection fraction 60% or an elevated end-systolic
dimension. Surgery is also reasonable (Class IIa) for patients
who have pulmonary hypertension at rest or new-onset
atrial fibrillation if they are candidates for mitral valve (MV)
repair. Exercise testing is helpful in many situations (4) for
determining if a patient is truly asymptomatic and in
identifying those who develop pulmonary hypertension with
exercise (60 mm Hg) (1,2).
These indications for MV surgery are reasonable if a
patient presents initially to the cardiologist with any of these
findings. However, in the longitudinal management of
asymptomatic patients with severe MR, would it be prefer-
able for patients to undergo surgery before these endpoints
Abbreviations
and Acronyms
ACC  American College of
Cardiology
AHA  American Heart
Association
AR  aortic regurgitation
AVR  aortic valve
replacement





ESC  European Society of
Cardiology
LV  left ventricular
MR  mitral regurgitation
MV  mitral valve
MVP  mitral valve
prolapse
STS  Society of Thoracic
Surgeons
Guideline Recommendations forS rg ry for Degenerative Mitral RegurgitationTable 1 Guideline R commendations forSurgery for Degenerative Mitral Regurgitation
Indication ACC/AHA ESC/EACTS
Symptomatic patients Class I Class I
Asymptomatic patients
LV systolic dysfunction* Class I Class I
Pulmonary hypertension
PASP 50 mm Hg at rest Class IIa Class IIa
PASP 60 mm Hg with exercise Class IIa Class IIb
Atrial fibrillation Class IIa Class IIa
Normal LV function, repair feasible Class IIa Class IIa†
This is a simplified table. See full guidelines (1,2) for complete recommendations. *Defined as
ejection fraction 60% or elevated end-systolic diameter (40 mm in ACC/AHA guidelines; 45
mm in ESC/EACTS guidelines). †Specifically for patients with flail leaflet and end-systolic dimen-
sion 40 mm; there is a separate class IIb recommendation for such patients with left atrial
volume index 60 ml/m2.
ACC/AHA  American College of Cardiology/American Heart Association; ESC/EACTS  Euro-s
pean Society of Cardiology/European Association for Cardio-Thoracic Surgery; LV left ventricular;
PASP  pulmonary artery systolic pressure.develop, because LV dysfunction, pulmonary hypertension,
or atrial fibrillation is not always reversible after surgery?
This question frames the debate whether all asymptomatic
patients with MVP and chronic severe MR should undergo
elective MV repair. This dilemma can only be settled with
a prospective randomized trial of elective MV repair versus
a strategy of “watchful waiting.”
One concern about a broad recommendation for MV
surgery in all asymptomatic patients with MVP and severe
MR in the United States is that many might be subject to
the long-term risks of prosthetic valves when they are
excellent candidates for MV repair. According to the
database of the Society of Thoracic Surgeons (STS) (5), the
frequency of MV repair for patients with MR in North
America, after excluding patients with mitral stenosis en-
docarditis, emergency surgery, previous heart surgery, and
concomitant coronary artery bypass graft (CABG) or aortic
valve surgery, has increased during the last decade but has
plateaued at just 70% (Fig. 1). Because the great majority
f such operations are for MVP or functional MR, one
ould anticipate that a higher percentage of patients are
andidates for MV repair.
The frequency of repair is just one aspect of the issue;
here are no data regarding the actual success rates of MV
epair in the United States in terms of elimination of MR.
esidual MR at hospital discharge has adverse implications
egarding the longevity of the repair and the likelihood that
dditional surgery may be necessary (6). In addition, despite
xcellent durability of a successful repair in most patients,
here is the risk of recurrent MR over the long term (6–9).
Assuming that a high-volume, high-quality surgical cen-
er can provide asymptomatic patients who have MVP and
Figure 1 Mitral Valve Repair 2000 Through 2007
Percentage of patients in the Society of Thoracic Surgeons Database undergo-
ing mitral valve repair for primary mitral regurgitation from 2000 through 2007.
Data include 47,126 patients at 910 hospitals. Patients with mitral stenosis,
endocarditis, previous cardiac surgery, shock, emergency surgery, and concom-
itant coronary artery bypass graft or aortic valve surgery are excluded.
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to clinical outcomes of a strategy of early MV repair.
Because MV repair will not improve symptoms in truly
asymptomatic patients, the issue is whether it will improve
long-term survival.
There are conflicting data regarding whether patients
with asymptomatic severe degenerative MR are at risk of
death before they develop the objective class I or IIa
indications for surgery. Four studies that observed asymp-
tomatic patients with severe degenerative MR have reported
markedly divergent findings regarding the risk of death in
those who are not referred for surgery (Table 2), with annual
mortality rates ranging from 0% to 8% per year (11–14). It
is noteworthy that the study reporting the highest mortality
rate (11) was a retrospective analysis of patients enrolled
between 1991 and 2000; these patients were managed by
their referring physicians and not the study investigators,
with many of them enrolled before the same investigators
had published their seminal papers describing the predictors
of outcome and before publication of the first ACC/AHA
guidelines in 1998. In contrast, the study with the lowest
mortality rate (12) followed patients prospectively and used
guideline recommendations as the only indications for
surgery. The 2 deaths related to MR in that study occurred
in patients who fulfilled the criteria for surgery but refused
to undergo the operation. Although it is true that the 2
series reporting the higher mortality rates (11,13) studied
patients who were older and had more severe LV dilation
(as a marker of severity of MR), these differences in
mortality among the 4 studies are not readily rationalized.
However, all 4 studies are consistent, and in keeping with
the earlier data of Rosen et al. (15), in demonstrating that
the rate at which patients with asymptomatic severe MR
develop symptoms or other objective indications for MV
surgery is relatively fast, with 30% to 40% of patients achieving
an indication for surgery over a 5-year period (Fig. 2). More-
over, Enriquez-Sarano et al. (11) quantified severity of MR
according to the current recommendations of the American
Society of Echocardiography (16) and showed that in
asymptomatic patients with severe MR (defined as an
effective regurgitant orifice area0.4 cm2), the likelihood of
emaining alive and asymptomatic without heart failure or
Mortality of Asymptomatic PatientsWith Degenerative MR Without SurgeryTable 2 Mortality of Asymptomatic PatientsWith Degenerative MR Without Surgery












Severe MR 198 8.4 61 61
Moderate MR 129 6.7 65 54
Rosenhek et al. (12) 132 0* 55 56
Grigioni et al. (13) 394 2.8 64 59
Kang et al. (14) 286 0.7 50 57
*2 deaths occurred in patients who fulfilled guideline criteria for surgery but refused the operation.
LVEDD  left ventricular end-diastolic dimension; MR  mitral regurgitation.trial fibrillation was only 36% at 5 years. Thus, indepen-ent of whether asymptomatic patients with severe MR are
t risk of dying, the majority will develop indications for
urgery within only a few years.
Although the risk of death before surgery is debatable, a
tronger argument for earlier surgery for severe MR can be
ade based on the survival results after MV surgery.
urvival results after MV repair are significantly related to
he presence and severity of preoperative symptoms. Post-
perative survival is equivalent to that of age and sex
atched normal subjects in patients who are New York
eart Association functional class I or II preoperatively,
hereas survival is significantly lower than expected in
atients who have developed New York Heart Association
unctional class III or IV symptoms before surgery (7,17). It
ollows that if surgery is delayed until patients exhibit
ignificant symptoms, many will have developed LV dys-
unction, pulmonary hypertension, and/or atrial fibrillation
hat may not be reversible and will affect survival adversely
fter otherwise successful MV repair. Thus, it is not
nreasonable to consider elective MV repair as a treatment
ption, in patients who are candidates for repair, if it can be
erformed in a center with a high likelihood of success and
t low risk.
On the basis of these considerations, the ACC/AHA
uidelines (1) conclude that it is reasonable to consider
Class IIa) MV repair in asymptomatic patients with severe
R in whom the likelihood of successful repair without
esidual MR is 90%, although the ESC/EACTS guide-
ines (2) recommend repair only in patients with a flail
eaflet and an LV end-systolic dimension 40 mm (Class
Ia) or those with left atrial dilation 60 ml/m2 (Class IIb).
The stronger class I statement in both guidelines is that MV
repair is preferable to MV replacement in patients with MR
who require surgery (1,2), and that patients should be
referred to surgical centers experienced in MV repair (1).
With the understanding that there are no prospective trials
Figure 2 Natural History of Degenerative Mitral Regurgitation
Natural history of asymptomatic patients with degenerative mitral regurgita-
tion and normal left ventricular systolic function. Data from Enriquez-Sarano
et al. (11), Rosenhek et al. (12), Grigioni et al. (13), Kang et al. (14),
Rosen et al. (15).
696 Bonow JACC Vol. 61, No. 7, 2013
Surgery for Valvular Regurgitation February 19, 2013:693–701comparing MV repair with replacement, the majority of
comparative studies indicate a survival advantage with repair
(8,18–20).
Although the criteria for an “experienced” surgical center
were not defined, there are data supporting the concept that
centers of excellence in MV surgery yield better patient
outcomes. Findings from the STS Database (21) demon-
strate that volume of MR surgery at the hospital level
(excluding patients who have mitral stenosis, previous car-
diac surgery, shock, or recent myocardial infarction and
those undergoing concomitant surgery except procedures on
the tricuspid valve) was significantly related to in-hospital
mortality after MV surgery, which in turn is related to the
likelihood that patients receive MV repair instead of re-
placement (Fig. 3). Although hospital volume is only a
rough surrogate for quality, similar outcomes have been
observed in Medicare data (22), with in-hospital mortality
rates after MV surgery twice as high in centers in the lowest
Figure 3 Hospital Volume of Mitral Valve Surgery
and Outcomes
Data linking volume of mitral valve surgery to in-hospital mortality and the fre-
quency of mitral valve repair. Data include 13,614 patients at 575 hospitals.
Hospitals are divided into quartiles of mitral valve surgery volume, with mortal-
ity at the lowest-volume centers set at 1.0. Patients with mitral stenosis, previ-
ous cardiac surgery, shock, recent myocardial infarction, and concomitant
surgery (other than tricuspid valve procedures) are excluded. Reprinted, with
permission, from Gammie et al. (21).decile of surgical volume compared with that in centers inthe highest volume decile (Fig. 4). These data at the
hospital level do not provide insights into outcomes of the
individual cardiac surgeon. However, Bolling et al. (23) have
tied procedural volume of individual surgeons performing
MV surgery to the likelihood of MV repair versus replace-
ment. Among 1,008 surgeons performing 28,507 MV
operations from 2007 to 2009 at 639 North American
hospitals in the STS Database, those performing a higher
volume of MV operations performed a higher percentage of
MV repairs. A striking finding in these data was that only 3
surgeons performed more than 100 MV operations per year
and only 16 performed more than 50 per year. The median
number of MV operations was only 5 per surgeon per year
(range 1 to 166), and the mean rate of MV repair was only
41% (range 0% to 100%). Thus, at both the hospital and the
provider level, there is strong evidence of variability in
surgical treatment, with the majority of patients undergoing
surgery by low-volume operators with a high likelihood of
receiving MV replacement instead of repair. Whether there
are volume thresholds or variations in care at the level of the
individual surgeon that translate into disparate survival
outcomes (as has been shown at the hospital level) will
require further study.
Bridgewater et al. (24) addressed the concept of centers of
excellence for MV surgery; recommended development of
multidisciplinary teams of surgeons, cardiologists, anesthe-
siologists, and nurses; and proposed 19 best practices for
MV repair. These criteria focus on surgical training, quality
control, and patient volume at the hospital and surgeon
level. Whether the volume thresholds they proposed (50 per
year for the hospital and 25 per year for the surgeon) are
possible in light of the data of Bolling et al. (23) noted
earlier is questionable. More important than volume alone,
auditing of surgical results was emphasized, with proposed
targets of 1% operative mortality and 5% 5-year reop-
Figure 4 Hospital Volume and
Outcome of Mitral Valve Replacement
Relationship between hospital volume and in-hospital mortality for mitral
valve replacement in patients enrolled in Medicare, including 61,252 mitral
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February 19, 2013:693–701 Surgery for Valvular Regurgitationeration rates (24). This underscores the principal that a
low-volume center can still be a high-quality center if there
is attention to quality. Finally, quality control of cardiology
ractice, echocardiography, and intraoperative transesophageal
chocardiography was also emphasized.
With or without a mandate for centers of excellence for
V surgery, there is also evidence of variability in physician
dherence to accepted recommendations for optimal patient
anagement, including large numbers of patients with
ymptomatic MR who are not referred for surgery (25–27).
t a time when there are strong currents toward earlier
urgery in asymptomatic patients with MR, there needs to
e renewed emphasis on the clear Class I recommendations
or surgery in symptomatic patients.
unctional MR
unctional MR stemming from LV dilation and remodel-
ng occurs commonly in patients with ischemic or dilated
ardiomyopathy and is the second leading cause of MR in
he United States and developed countries of the world (28).
ecause this is a disease of the myocardium and not the
alve itself, uncertainty exists regarding the indications for
rimary MV surgery.
Current evidence clearly indicates that the presence of
unctional MR identifies a higher risk group among patients
ith LV systolic dysfunction and that increasing severity of
R adds incrementally to this risk (29,30). Although mild
R in patients with primary degenerative MR is well
olerated for years, even mild functional MR in a patient
ith a low ejection fraction has important adverse prognos-
ic implications. What is less clear is whether functional MR
s merely a marker of severity of LV dysfunction or whether
ts attendant volume load contributes to progressive LV
ysfunction and is thus a target for therapy.
Therapies that produce beneficial reverse LV remodeling
nd reduction in LV volume, such as beta-adrenergic
lockade or cardiac resynchronization therapy, reduce the
everity of functional MR (31–33) and also improve out-
omes in terms of survival and quality of life. It does not
ecessarily follow that interventions primarily targeted to
educe MR will have similar beneficial effects in addition to,
r instead of, optimal medical therapy. To the best of my
nowledge, there are no prospective studies demonstrating
his effect. A retrospective study using propensity analyses
ailed to show a benefit of surgery compared with medical
reatment of functional MR (34), and another study failed
o show any benefit of CABG plus MV repair compared
ith CABG alone in patients with ischemic functional MR
35). Moreover, unlike repair of degenerative MR, in which
uccessful repair has established durability for decades
7,8,36), functional MR commonly recurs after initially
uccessful MV repair because of the progressive nature of
he underlying ventricular disease (37). This situation cre-
tes the additional uncertainty of whether the more advan-tageous surgical approach to functional MR is MV replace-
ment instead of MV repair.
The National Heart, Lung, and Blood Institute’s Car-
diothoracic Surgical Trials Network is addressing several of
these surgical issues through its 2 ongoing clinical trials of
surgical treatment of functional MR (38). However, neither
of these trials compares the surgical option versus medical
management alone in patients with functional MR.
In the absence of data firmly supporting the role of
surgery in functional MR, the ACC/AHA and ESC/
EACTS guidelines (1,2) provide few specific recommenda-
tions for surgery (Table 3), and there is clear need for
further investigation. There may also be a role for trans-
catheter MV repair in this condition (39), and future
prospective trials could conceivably address this approach as
well.
Aortic Regurgitation
As is the case in patients with MR, there is continuing
uncertainty and considerable controversy regarding the timing
of surgical intervention in patients with AR. Like those with
MR, patients with AR often remain asymptomatic with
normal LV systolic function for many years despite the
substantial LV volume overload; however, by the time
symptoms develop, a large number may have developed
myocardial dysfunction, placing them at high risk for
postoperative heart failure and death (40,41). Unlike the
trend for early surgery in asymptomatic patients with severe
degenerative MR, the majority of whom are candidates for
MV repair, a higher threshold for surgery is set for patients
with AR as they almost always face aortic valve replacement
(AVR). Despite advances in aortic valve repair, especially in
young patients with bicuspid aortic valves (42), the experi-
ence at a few specialized centers has not yet permeated into
the expertise at the general community level, and durability
of aortic valve repair remains a major concern.
AVR is clearly warranted in patients who have symp-
toms (40,41), and virtually every study that has examined
Guideline Recommendationsfor Surg ry for Functional MRTable 3 Guideline Recommendationsfor Surgery for Functional MR
Indication ACC/AHA ESC/EACTS
Severe MR, EF 30%, undergoing CABG Class I
Moderate MR, undergoing CABG Class IIa
Severe MR, EF 30%, option for CABG and
evidence of viability
Class IIa
Severe MR, EF 30%, no option for CABG,
symptoms despite optimal medical
therapy (including CRT), low comorbidity
Class IIb
Severe MR, EF 30%, NYHA FC III–IV
symptoms desipte optimal medical
therapy (including CRT)
Class IIb
This is a simplified table. See full guidelines (1,2) for complete recommendations.
CABG  coronary artery bypass graft; CRT  cardiac resynchronization therapy; EF  ejection
fraction; MRmitral regurgitation; NYHA FC New York Heart Association functional class; other
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volume) as significant prognostic variables (1,40,41,43).
ence, the development of symptoms or a subnormal LV
jection fraction is a Class I recommendation for AVR
Table 4) (1,2).
A strategy to intervene before symptoms and/or LV
ystolic dysfunction develop might also be considered, but
ata supporting pre-emptive surgery in patients with severe
R are less compelling than in patients with severe MR.
nlike the decision for MV repair, the decision for replac-
ng the aortic valve, and then selecting a mechanical
rosthesis versus a bioprosthesis, can be an agonizing
ecision when dealing with an asymptomatic patient. In
ddition, the time course toward symptom onset or LV
ystolic dysfunction in asymptomatic AR is more gradual
nd protracted than in MR, especially in younger patients
1,44–46), with an average event rate of only 4% per year.
he 3 largest natural history studies (44–46) provide similar
ata regarding the rate at which clinical events (death,
ymptoms, or LV systolic dysfunction) develop in asymp-
omatic patients (Fig. 5). Because the majority of such
vents represent the onset of symptoms leading to timely
nd successful AVR, these endpoints are usually not irre-
rievable. Hence, a detailed history probing for symptoms
emains the most important test in the initial and serial
valuation of patients with AR. However, it is also apparent
hat death or asymptomatic LV dysfunction represents more
han 33% of the clinical events, and thus more objective
esting beyond a careful history is required as part of the
ngoing evaluation of asymptomatic patients. The series
hich provide longitudinal data indicate that patients likely
o develop symptoms or LV systolic dysfunction can be
dentified, both at initial evaluation and during serial stud-
es, on the basis of the magnitude of LV dilation and the LV
jection fraction response to exercise (1,44–46). The guide-
ines make the point that severity of the volume load is an
mportant variable to observe (Table 4) (1,2). These guide-
ine recommendations have not been tested prospectively,
ut a long-term postoperative study (47) has demonstrated
mproved survival when patients undergo early AVR after
nset of mild symptoms, mild LV dysfunction (ejection
raction 45% to 50%) or end-systolic dimension 50 to 55
Guideline Recommendations forS rg ry in Patients With Aortic RegurgitationTable 4 Guideline Recommendations forSurgery in Patients With Aortic Regurgitation
Indication ACC/AHA ESC/EACTS
Symptomatic patients Class I Class I
Undergoing CABG or surgery on aorta or
another valve
Class I Class I
Asymptomatic patients
LV systolic dysfunction (EF 50%) Class I Class I
Severe LV dilation (LVEDD 75 mm or
ESD 55 mm)
Class IIa —
Progressive LV dilation (LVEDD 70 mm or
ESD 50 mm)
Class IIb Class IIaThis is a simplified table. See full guidelines (1,2) for complete recommendations.
ESD  end-systolic dimension; other abbreviations as in Tables 1, 2, and 3.m rather than waiting for more severe symptoms or more
evere LV dysfunction to develop (Fig. 6). Whether LV
ystolic and diastolic dimensions should be indexed to body
ize is uncertain, as the most appropriate index (such as
ody surface area or body mass index) has not been
etermined and there are limited data regarding the thresh-
lds with which to recommend AVR (41). Guidelines
otwithstanding, it would be acceptable to recommend
VR in a patient with severe AR when there are steady and
rogressive increases in LV volume or decreases in ejection
raction on serial studies. Optimal timing of AVR is often
ore of an art than a science. More objective markers of
mpending myocardial dysfunction are needed, but these
emain elusive.
Figure 5 Natural History of
Asymptomatic Aortic Regurgitation
Natural history of asymptomatic patients with aortic regurgitation and normal
left ventricular systolic function. Data from Bonow et al. (44), Tornos et al.
(45), and Borer et al. (46). Asymp LVD  asymptomatic left ventricular dysfunc-
tion (ejection fraction 50%); LV  left ventricular.
Figure 6 Survival After Aortic Valve Replacement
for Aortic Regurgitation
Long-term survival after valve replacement for aortic regurgitation demonstrat-
ing improved outcome with early surgery. Reprinted, with permission, from Tor-
nos et al. (47). EF  ejection fraction; ESD  end-systolic dimension; NYHA 
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LV ejection fraction and internal dimensions alone may not
be sufficient in all patients. In addition to the inherent
variability of these measurements, ejection fraction notori-
ously fluctuates depending on blood pressure and other
loading conditions, and LV short-axis diameters fail to
adequately reflect the great individual variation in the
3-dimensional geometries of volume-loaded left ventricles.
There is a paucity of new emerging evidence to guide
management decisions and change the current recommen-
dations for AVR. The guideline recommendations are
grounded on the methods that were available more than 2
decades ago when the long-term natural history and post-
operative outcome studies providing the bulk of the existing
evidence base were performed. Rather than relying on
1-dimensional LV diameters, there is a great need for
rigorous prospective assessments of LV geometry, volume,
and regional and global systolic performance that are now
possible with our current advanced imaging capabilities
(48). Only recently have standardized criteria for LV vol-
ume measurements by using echocardiography been estab-
lished (49), and these have not been subjected to extensive
long-term studies in sufficiently large numbers of patients.
In the single paper thus far investigating LV volume
measurements as a predictor of outcome in asymptomatic
patients with AR and normal LV ejection fraction, Detaint
et al. (50) demonstrated that volumetric measures are
superior to LV linear diameters in identifying patients who
are at risk of death, atrial fibrillation, or heart failure. This
study also showed that quantitative measures of regurgitant
volume and regurgitant fraction are more powerful than the
current guideline indicators. These findings illustrate the
potential for more advanced measures to provide better
discrimination than the standard measures currently in
routine use.
It is notable that the patients studied by Detaint et al.
(50) also had a much higher rate of events than reported in
the previous natural history studies referenced in the guide-
lines (1), including a 10-fold higher risk of death (2.2% per
year) compared with the average mortality rate in the
previous studies (0.2% per year). The higher rate of fatal and
nonfatal events reported by Detaint et al. (50) may be
explained by important age differences: 60 years in patients
in that report compared with an average of 39 years in the
natural history series cited in the guidelines (1). Older
patients with asymptomatic AR may have a higher clinical
event rate than younger patients because of concomitant
coronary artery disease. Alternatively, a significant volume
load may be less well tolerated in older individuals who have
reduced vascular compliance and increased myocardial stiff-
ness. This underscores the need for additional novel mea-
sures of cardiovascular structure and performance beyond
the current standards of LV dimensions, volumes, and
ejection fraction.
Newer methods to assess systolic and diastolic myocardial
function by using tissue Doppler imaging and speckletracking are now available, and cardiac magnetic resonance
has the potential to identify and quantify interstitial fibrosis
developing as part of the chronic hypertrophic process. Such
findings may hold a key for earlier intervention. Although
these have been evaluated more extensively in patients with
aortic stenosis (51–53), work is forthcoming in those with
AR (54,55). There is also the need to identify serum
biomarkers that herald impending myocardial dysfunction.
These will require careful prospective investigation to de-
termine their potential role in clinical decision making
regarding the indications for AVR (56). The prediction of
surrogate measures, such as changes in LV volume and
function after surgery, is no longer adequate. To move the
needle toward earlier surgical indications will require dem-
onstration that new measures predict improved survival.
The poor outcome of patients with severe preoperative LV
dysfunction and persistent dysfunction after AVR reported
in previous decades may no longer be pertinent in the
current era of better surgical techniques, aggressive medical
therapy for heart failure, and availability of biventricular
pacemakers and implantable cardioverter defibrillators (57).
onclusions
n patients with valvular regurgitation, the goal is to operate
ate enough in the natural history of the disease to justify the
isks of intervention but early enough to prevent irreversible
V dysfunction, pulmonary hypertension, and/or chronic
rrhythmias. The balance between natural history versus the
hort- and long-term risks of surgery clearly favors inter-
ention in symptomatic patients and those with LV dys-
unction. As the balance shifts toward earlier intervention in
symptomatic patients, it is essential that patients be re-
erred to surgical centers with established excellence in MV
epair and AVR. It is equally important that patients be
valuated by cardiologists who have sufficient expertise and
linical judgment in determining the optimal time for
aking the referral for surgery. The management of pa-
ients with valvular heart disease has been hampered by the
ack of definitive prospective clinical trials. Clinical trials to
etermine whether surgery or conservative management is
he most appropriate strategy for patients with severe
symptomatic MR or AR, and to determine the most
ffective methods for risk stratification, are needed to guide
he future management of these prevalent conditions.
Reprint requests and correspondence: Dr. Robert O. Bonow,
Center for Cardiovascular Innovation, Northwestern University Fein-
berg School of Medicine, 645 North Michigan Avenue, Suite 1006,
Chicago, Illinois 60611. E-mail: r-bonow@northwestern.edu.
REFERENCES
1. Bonow RO, Carabello B, Chatterjee K, et al. ACC/AHA 2006
guidelines for the management of patients with valvular heart disease.
A report of the American College of Cardiology/American Heart
Association Task Force on Practice Guidelines. J Am Coll Cardiol
2006;48:e1–148.
700 Bonow JACC Vol. 61, No. 7, 2013
Surgery for Valvular Regurgitation February 19, 2013:693–7012. Vahanian A, Alfieri O, Andreotti F, et al. Guidelines on the
management of valvular heart disease (version 2012). The Joint Task
Force on the Management of Valvular Heart Disease of the European
Society of Cardiology (ESC) and the European Association for
Cardio-Thoracic Surgery (EACTS). Eur Heart J 2012;33:2451–96.
3. Tricoci P, Allen KM, Kramer JM, Califf RM, Smith SC Jr. Scientific
evidence underlying the ACC/AHA clinical practice guidelines.
JAMA 2009;301:831–41.
4. Picano E, Pibarot P, Lancellotti P, Monin JL, Bonow RO.The
emerging role of exercise testing and stress echocardiography in
valvular heart disease. J Am Coll Cardiol 2009;54:2251–60.
5. Gammie JS, Sheng S, Griffith BP, et al. Trends in mitral valve surgery
in the United States: results from the Society of Thoracic Surgeons
Adult Cardiac Database. Ann Thorac Surg 2009;87:1431–9.
6. Mohty D, Orszulak TA, Schaff HV, Avierinos JF, Tajik JA,
Enriquez-Sarano M. Very long-term survival and durability of mitral
valve repair for mitral valve prolapse. Circulation 2001;104:I1–7.
7. David TE, Ivanov J, Armstrong S, Rakowski H. Late outcomes of
mitral valve repair for floppy valves: implications for asymptomatic
patients. J Thorac Cardiovasc Surg 2003;125:1143–52.
8. Suri RM, Schaff HV, Dearani JA, et al. Survival advantage and
improved durability of mitral repair for leaflet prolapse subsets in the
current era. Ann Thorac Surg 2006;82:819–27.
9. Flameng W, Meuris B, Herijgers P, Herregods MC. Durability of
mitral valve repair in Barlow disease versus fibroelastic deficiency.
J Thorac Cardiovasc Surg 2008;135:274–82.
10. Castillo JG, Anyanwu AC, Fuster V, Adams DH. A near 100% repair
rate for mitral valve prolapse is achievable in a reference center:
implications for future guidelines. J Thorac Cardiovasc Surg 2012;144:
308–12.
11. Enriquez-Sarano M, Avierinos JF, Messika-Zeitoun D, et al. Quan-
titative determinants of the outcome of asymptomatic mitral regurgi-
tation. N Engl J Med 2005;352:875–83.
12. Rosenhek R, Rader F, Klaar U, et al. Outcome of watchful waiting
in asymptomatic severe mitral regurgitation. Circulation 2006;113:
2238–44.
13. Grigioni F, Tribouilloy C, Avierinos JF, et al. Outcomes in mitral
regurgitation due to flail leaflets: a multicenter European study. J Am
Coll Cardiol Img 2008;1:133–41.
14. Kang DH, Kim JH, Rim JH, et al. Comparison of early surgery versus
conventional treatment in asymptomatic severe mitral regurgitation.
Circulation 2009;119:797–804.
15. Rosen S, Borer JS, Hochreiter C, et al. Natural history of the
asymptomatic/minimally symptomatic patient with severe mitral re-
gurgitation secondary to mitral valve prolapse and normal right and left
ventricular performance. Am J Cardiol 1994;74:374–80.
16. Zoghbi WA, Enriquez-Sarano M, Foster E, et al. Recommendations
for evaluation of the severity of native valvular regurgitation with
two-dimensional and Doppler echocardiography. J Am Soc Echocar-
diogr 2003;16:777–802.
17. Tribouilloy CM, Enriquez-Sarano M, Schaff HV, et al. Impact of
preoperative symptoms on survival after surgical correction of organic
mitral regurgitation: rationale for optimizing surgical indications.
Circulation 1999;99:400–5.
18. Jokinen JJ, Hipeläinen MJ, Pitkänen OA, Hartikainen JE. Mitral valve
replacement versus repair: propensity-adjusted survival and quality-of-
life analysis. Ann Thorac Surg 2007;84:451–8.
19. Shuhaiber J, Anderson RJ. Meta-analysis of clinical outcomes follow-
ing surgical mitral valve repair or replacement. Eur J Cardiothorac
Surg 2007;31:267–75.
20. Chikwe J, Goldstone AB, Passage J, et al. A propensity score-
adjusted retrospective comparison of early and mid-term results of
mitral valve repair versus replacement in octogenarians. Eur Heart J
2011;32:618–26.
21. Gammie JS, O’Brien SM, Griffith BP, Ferguson TB, Peterson ED.
Influence of hospital procedural volume on care process and mortality
for patients undergoing elective surgery for mitral regurgitation.
Circulation 2007;115:881–6.
22. Goodney PP, O’Connor GT, Wennberg DE, Birkmeyer JE. Do
hospitals with low mortality rates in coronary artery bypass also
perform well in valve replacement? Ann Thorac Surg 2003;76:1131–7.
23. Bolling SF, Li S, O’Brien SM, Brennan JM, Prager RL, Gammie JS.
Predictors of mitral valve repair: clinical and surgeon factors. Ann
Thorac Surg 2010;90:1904–12.24. Bridgewater B, Hooper T, Munsch C, et al. Mitral repair best practice:
proposed standards. Heart 2006;92:939–44.
25. Mirabel M, Iung B, Baron G, et al. What are the characteristics of
patients with severe, symptomatic, mitral regurgitation who are denied
surgery? Eur Heart J 2007;28:1358–65.
26. Toledano K, Rudski LG, Huynh T, Béïque F, Sampalis J, Morin J.
Mitral regurgitation: determinants of referral for cardiac surgery by
Canadian cardiologists. Can J Cardiol 2007;23:209–14.
27. Bach DS, Awaia M, Gurm HS, Kohnstamm S. Valvular heart disease:
failure of guideline adherence for intervention in patients with severe
mitral regurgitation. J Am Coll Cardiol 2009;54:860–5.
28. Levine RA, Schwammenthal E. Ischemic mitral regurgitation on the
threshold of a solution: from paradoxes to unifying concepts. Circu-
lation 2005;112:745–58.
29. Grigioni F, Enriquez-Sarano M, Zehr KJ, Bailey KR, Tajik AJ.
Ischemic mitral regurgitation: long-term outcome and prognostic
implications with quantitative Doppler assessment. Circulation 2001;
103:1759–64.
30. Deja MA, Grayburn PA, Sun B, et al. Influence of mitral regurgitation
repair on survival in the Surgical Treatment for Ischemic Heart Failure
trial. Circulation 2012;125:2639–48.
31. Capomolla S, Febo O, Gnemmi M, et al. -Blockade therapy in
chronic heart failure: diastolic function and mitral regurgitation
improvement by carvedilol. Am Heart J 2000;139:596–608.
32. St. John SuttonMG, Plappert T, AbrahamWT, et al. Effect of cardiac
resynchronization therapy on left ventricular size and function in
chronic heart failure. Circulation 2003;107:1985–90.
33. Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update
incorporated into the ACC/AHA 2005 guidelines for the diagnosis
and management of heart failure in adults: a report of the American
College of Cardiology Foundation/American Heart Association Task
Force on Practice Guidelines Developed in Collaboration With the
International Society for Heart and Lung Transplantation. J Am Coll
Cardiol 2009;53:e1–90.
34. Wu AH, Aaronson KD, Bolling SF, Pagani FD, Welch K, Koelling
TM. Impact of mitral valve annuloplasty on mortality risk in patients
with mitral regurgitation and left ventricular systolic dysfunction. J Am
Coll Cardiol 2005;45:381–7.
35. Mihaljevic T, Lam BK, Rajeswaran J, et al. Impact of mitral valve
annuloplasty combined with revascularization in patients with
functional ischemic mitral regurgitation. J Am Coll Cardiol 2007;
49:2191–201.
36. Braunberger E, Deloche A, Berrebi A, et al. Very long-term results
(more than 20 years) of valve repair with Carpentier’s techniques in
nonrheumatic mitral valve insufficiency. Circulation 2001;104:I8–11.
37. McGee EC, Gillinov AM, Blackstone EH, et al. Recurrent mitral
regurgitation after annuloplasty for functional ischemic mitral regur-
gitation. J Thorac Cardiovasc Surg 2004;128:916–24.
38. O’Gara PT, Garner T. The Cardiothoracic Surgery Network: ran-
domized clinical trials in the operating room. J Thorac Cardiovasc
Surg 2010;139:830–4.
39. Auricchio A, Schillinger W, Meyer S, et al. Correction of mitral
regurgitation in nonresponders to cardiac resynchronization therapy by
MitraClip improves symptoms and promotes reverse remodeling.
J Am Coll Cardiol 2011;58:2183–9.
40. Bonow RO, Dodd JT, Maron BJ, et al. Long-term serial changes in
left ventricular function and reversal of ventricular dilatation after valve
replacement for chronic aortic regurgitation. Circulation 1988;78:
1108–20.
41. Dujardin KS, Enriquez-Sarano M, Schaff HV, Bailey KR, Seward JB,
Tajik AJ. Mortality and morbidity of aortic regurgitation in clinical
practice: a long-term follow-up study. Circulation 1999;99:1851–7.
42. Pettersson GB, Crucean AC, Savage R, et al. Toward predictable
repair of regurgitant aortic valves: a systematic morphology-directed
approach to bicommissural repair. J Am Coll Cardiol 2008;52:40–9.
43. Klodas E, Enriquez-Sarano M, Tajik AJ, et al. Aortic regurgitation
complicated by extreme left ventricular dilation: long-term outcome
after surgical correction. J Am Coll Cardiol 1996;27:670–7.
44. Bonow RO, Lakatos E, Maron BJ, Epstein SE. Serial long-term
assessment of the natural history of asymptomatic patients with
chronic aortic regurgitation and normal left ventricular systolic func-
tion. Circulation 1991;84:1625–35.
701JACC Vol. 61, No. 7, 2013 Bonow
February 19, 2013:693–701 Surgery for Valvular Regurgitation45. Tornos MP, Olona M, Permanyer-Miralda G, et al. Clinical outcome
of severe asymptomatic chronic aortic regurgitation: a long term
prospective follow up study. Am Heart J 1995;130:333–9.
46. Borer JS, Hochreiter C, Herrold E, et al. Prediction of indications for
valve replacement among asymptomatic or minimally symptomatic
patients with chronic aortic regurgitation and normal left ventricular
performance. Circulation 1998;97:525–34.
47. Tornos P, Sambola A, Permanyer-Miralda G, Evangelista A, Gomez
Z, Soler-Soler J. Long-term outcome of surgically treated aortic
regurgitation: influence of guideline adherence toward early surgery.
J Am Coll Cardiol 2006;47:1012–7.
48. Schiros CG, Dell’Italia LJ, Gladden JD, et al. Magnetic resonance
imaging with 3-dimensional analysis of left ventricular remodeling in
isolated mitral regurgitation: implications beyond dimensions. Circu-
lation 2012;125:2334–42.
49. Lang RM, Bierig M, Devereux RB, et al. Recommendations for
chamber quantification: a report from the American Society of
Echocardiography’s Guidelines and Standards Committee and the
Chamber Quantification Writing Group, developed in conjunction
with the European Association of Echocardiography, a branch of the
European Society of Cardiology. J Am Soc Echocardiogr 2005;18:
1440–63.
50. Detaint D, Messika-Zeitoun D, Maalouf J, et al. Quantitative echo-
cardiographic determinants of clinical outcome in asymptomatic pa-
tients with aortic regurgitation: a prospective study. J Am Coll Cardiol
Img 2008:1:1–11.51. Dweck MR, Joshi S, Murigu T, et al. Midwall fibrosis is an
independent predictor of mortality in patients with aortic stenosis.
J Am Coll Cardiol 2011;58:1271–9.
52. Herrmann S, Störk S, Niemann M, et al. Low-gradient aortic valve
stenosis: myocardial fibrosis and its influence on function and out-
come. J Am Coll Cardiol 2011;58:402–12.
53. Ng ACT, Delgado V, Bertini M, et al. Alterations in multidirectional
myocardial functions in patients with aortic stenosis and preserved
ejection fraction: a two-dimensional speckle tracking analysis. Eur
Heart J 2011;32:1542–50.
54. Olsen NT, Sogaard P, Larsson HB, et al. Speckle tracking echocar-
diography for predicting outcome in chronic aortic regurgitation
during conservative management and after surgery. J Am Coll Cardiol
Img 2011;4:223–30.
55. Bonow RO. Aortic regurgitation: time to reassess timing of valve
replacement? J Am Coll Cardiol Img 2011;4:231–3.
56. Pizzaro R, Bazzino OO, Oberti PF, et al. Prospective validation of the
prognostic usefulness of B-type natriuretic peptide in asymptomatic
patients with chronic aortic regurgitation. J Am Coll Cardiol 2011;
58:1705–14.
57. Bhudia SK, McCarthy PM, Kumpati GS, et al. Improved outcomes
after aortic valve surgery for chronic aortic regurgitation with severe
left ventricular dysfunction. J Am Coll Cardiol 2007;49:1465–71.Key Words: regurgitation y surgery y valvular.
